Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Indiva Limited stock logo
NDVA
Indiva
C$0.03
-14.3%
C$0.03
C$0.02
C$0.13
C$5.87M1.12119,038 shs558,384 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$5.65
-4.7%
$5.16
$4.32
$14.45
$819.75M1.221.37 million shs1.25 million shs
Zomedica Corp. stock logo
ZOM
Zomedica
$0.12
$0.09
$0.17
$95.35M1.034.62 million shs790,936 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Indiva Limited stock logo
NDVA
Indiva
0.00%0.00%0.00%0.00%0.00%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-4.72%+2.91%+7.62%+2.17%-32.50%
Zomedica Corp. stock logo
ZOM
Zomedica
0.00%0.00%0.00%0.00%-32.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Indiva Limited stock logo
NDVA
Indiva
N/AN/AN/AN/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
3.601 of 5 stars
3.44.00.00.02.13.31.3
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Indiva Limited stock logo
NDVA
Indiva
0.00
N/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.88
Moderate Buy$30.25435.40% Upside
Zomedica Corp. stock logo
ZOM
Zomedica
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest VIR, ZOM, and NDVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
5/22/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
5/12/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $14.00
4/17/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $21.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Indiva Limited stock logo
NDVA
Indiva
C$37.57M0.16C$0.01 per share5.20N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$74.21M10.52N/AN/A$8.35 per share0.68
Zomedica Corp. stock logo
ZOM
Zomedica
$25.19M0.00N/AN/A$0.24 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Indiva Limited stock logo
NDVA
Indiva
-C$4.92M-C$0.03N/AN/A-13.09%-544.76%-3.51%N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$521.96M-$4.22N/AN/AN/A-2,769.04%-47.46%-39.33%7/30/2025 (Estimated)
Zomedica Corp. stock logo
ZOM
Zomedica
-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/A

Latest VIR, ZOM, and NDVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.83N/AN/AN/AN/AN/A
5/7/2025Q1 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Indiva Limited stock logo
NDVA
Indiva
N/A4.04%N/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Indiva Limited stock logo
NDVA
Indiva
5,899.22
0.72
0.52
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
6.79
6.79
Zomedica Corp. stock logo
ZOM
Zomedica
N/A
10.82
10.15

Institutional Ownership

CompanyInstitutional Ownership
Indiva Limited stock logo
NDVA
Indiva
0.06%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%
Zomedica Corp. stock logo
ZOM
Zomedica
8.95%

Insider Ownership

CompanyInsider Ownership
Indiva Limited stock logo
NDVA
Indiva
36.29%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
16.00%
Zomedica Corp. stock logo
ZOM
Zomedica
4.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Indiva Limited stock logo
NDVA
Indiva
147,000195.49 millionN/ANot Optionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
580138.24 million116.12 millionOptionable
Zomedica Corp. stock logo
ZOM
Zomedica
50979.95 million938.89 millionNot Optionable

Recent News About These Companies

15 Cheapest Stocks Insiders Are Buying In March
Q4 2024 Zomedica Corp Earnings Call
Zomedica Corp. (ZOMDF) Q4 2024 Earnings Call Transcript
Zomedica (ZOMDF) Gets a Buy from Noble Financial
Zomedica Corp.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Indiva stock logo

Indiva CVE:NDVA

C$0.03 -0.01 (-14.29%)
As of 06/12/2024

Indiva Limited engages in the production, processing, and sale of cannabis and cannabis related products in Canada. It offers pre-rolls, flower, capsules, and edible and extract products under the INDIVA, Indiva Life, and Artisan Batch brands. The company produces and distributes the Bhang Chocolate, Wana Sour Gummies, Jewels Chewable Tarts, Grön edibles, and Dime Industries vape products through license agreements and partnerships. Indiva Limited is based in Ottawa, Canada.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$5.65 -0.28 (-4.72%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$5.63 -0.02 (-0.42%)
As of 07/11/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Zomedica stock logo

Zomedica NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.